Table 1.
Receptor occupancy (RO) in eight cell types in three replicate experiments with the same patient PBL sample
| (a) ROraw and ROstandardized in patient PBLs saturated in vitro with natalizumab with expected RO of 100%. | ||||||
|---|---|---|---|---|---|---|
| RO raw | RO standard zed | |||||
| Day 1 | Day 2 | Day 3 | Day 1 | Day 2 | Day 3 | |
| Mem B cell | 120% | 129% | 132% | 98% | 105% | 111% |
| Monocyte | 114% | 108% | 113% | 94% | 89% | 95% |
| CD4 T CM | 115% | 110% | 122% | 92% | 86% | 101% |
| CD4 T EM | 114% | 116% | 126% | 92% | 94% | 106% |
| CD4 T EMRA | 116% | 130% | 129% | 93% | 102% | 107% |
| CD8 T CM | 129% | 127% | 148% | 103% | 101% | 123% |
| CD8 T EM | 123% | 125% | 131% | 99% | 100% | 110% |
| CD8 T EMRA | 130% | 132% | 147% | 105% | 106% | 123% |
| (b) ROraw, ROstandardized, ROvs100%raw, and ROvs100%standardized in patient PBL with unknown RO (i.e., not incubated with natalizumab in vitro). | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RO raw | RO standardized | RO vs. 100% raw | RO vs. 100% standardized | |||||||||
| Day 1 | Day 2 | Day 3 | Day 1 | Day 2 | Day 3 | Day 1 | Day 2 | Day 3 | Day 1 | Day 2 | Day 3 | |
| Mem B cell | 101% | 95% | 96% | 82% | 77% | 81% | 84% | 73% | 73% | 83% | 73% | 73% |
| Monocyte | 76% | 72% | 76% | 62% | 59% | 64% | 67% | 67% | 67% | 66% | 66% | 67% |
| CD4 T CM | 73% | 77% | 82% | 57% | 60% | 68% | 63% | 70% | 67% | 62% | 69% | 67% |
| CD4 T EM | 77% | 75% | 79% | 61% | 59% | 66% | 68% | 64% | 63% | 66% | 63% | 62% |
| CD4 T EMRA | 95% | 89% | 94% | 75% | 69% | 78% | 82% | 68% | 73% | 81% | 68% | 73% |
| CD8 T CM | 85% | 84% | 93% | 67% | 66% | 78% | 66% | 66% | 63% | 65% | 66% | 63% |
| CD8 T EM | 86% | 88% | 87% | 68% | 70% | 73% | 70% | 70% | 66% | 69% | 70% | 66% |
| CD8 T EMRA | 82% | 87% | 86% | 65% | 69% | 72% | 63% | 66% | 59% | 62% | 65% | 59% |